{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:29:38Z","timestamp":1791638978313,"version":"4.3.4"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2026,1,14]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Cefiderocol (FDC) is a siderophore cephalosporin approved for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (MDR-GNB), including carbapenem-resistant (CR) isolates. However, interpretation criteria for both broth microdilution (BMD) and disk diffusion (DD) methods differ among Clinical and Laboratory Standards Institute (CLSI), European Committee on Antimicrobial Susceptibility Testing (EUCAST), and U.S. Food and Drug Administration (FDA) guidelines. This study aimed to assess the categorical agreement (CA) between minimum inhibitory concentrations (MICs) determined by the BMD method and inhibition zone diameters measured by the DD method for FDC, using different interpretive breakpoints across various Gram-negative bacilli (GNB) isolates. A total of 1,170 GNB isolates were collected, including CR and carbapenem-susceptible (CS) isolates of\n                      <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">Klebsiella oxytoca<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">Enterobacter cloacae<\/jats:italic>\n                      complex,\n                      <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">Acinetobacter baumannii-calcoaceticus<\/jats:italic>\n                      complex. Isolates of\n                      <jats:italic toggle=\"yes\">Stenotrophomonas maltophilia<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">Burkholderia cepacia<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">Elizabethkingia anophelis<\/jats:italic>\n                      \u2014which are not categorized by carbapenem susceptibility\u2014were also included. The CA and error rates (minor error, major error, and very major error) were calculated using MIC interpretation as the reference. Among CR isolates, CA based on CLSI breakpoints ranged from 90.0% to 100% across species. U.S. FDA criteria showed comparable performance, except for\n                      <jats:italic toggle=\"yes\">A. baumannii-calcoaceticus<\/jats:italic>\n                      complex, where CA was lower (63.0%). In contrast, EUCAST breakpoints demonstrated greater variability, with CA ranging from 66.7% to 100%. Among CS isolates, CA was generally high (\u226587.5%) across most standards and species, with exceptions including EUCAST in the\n                      <jats:italic toggle=\"yes\">E. cloacae<\/jats:italic>\n                      complex (63.0%) and U.S. FDA in\n                      <jats:italic toggle=\"yes\">A. baumannii-calcoaceticus<\/jats:italic>\n                      complex (73.7%). In conclusion, CLSI breakpoints demonstrated the highest consistency between DD and BMD methods.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>IMPORTANCE<\/jats:title>\n                    <jats:p>\n                      Cefiderocol is one of the few remaining treatment options for infections caused by carbapenem-resistant Gram-negative bacilli (GNB). Accurate interpretation of susceptibility testing is essential for guiding effective therapy. However, discrepancies among breakpoints established by the Clinical and Laboratory Standards Institute, the European Committee on Antimicrobial Susceptibility Testing, and the U.S. Food and Drug Administration may result in inconsistent interpretations, particularly when using the disk diffusion (DD) method, which is more practical in many clinical laboratories. This study compares the categorical agreement between broth microdilution and DD method interpretations for Gram-negative bacilli across multiple guidelines and highlights the potential for misclassification. It also provides susceptibility data for\n                      <jats:italic toggle=\"yes\">Burkholderia cepacia<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">Elizabethkingia anophelis<\/jats:italic>\n                      , for which established interpretive criteria are currently lacking.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/jcm.01255-25","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T14:58:09Z","timestamp":1765378689000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":6,"title":["Interpretive agreement of susceptibility between broth microdilution and disk diffusion methods for cefiderocol, using criteria from the Clinical and Laboratory Standards Institute, European Committee on Antimicrobial Susceptibility Testing, and the Food and Drug Administration"],"prefix":"10.1128","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3815-6305","authenticated-orcid":true,"given":"Yu-Tzu","family":"Lin","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00v408z34","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medical Laboratory Science and Biotechnology, China Medical University","place":["Taichung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu-Hsien","family":"Lin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0368s4g32","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Laboratory Medicine, China Medical University Hospital, China Medical University","place":["Taichung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hao","family":"Chen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0368s4g32","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, China Medical University","place":["Taichung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Hao","family":"Tseng","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0368s4g32","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Laboratory Medicine, China Medical University Hospital, China Medical University","place":["Taichung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Wang","family":"Ho","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0368s4g32","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, China Medical University","place":["Taichung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7502-9225","authenticated-orcid":true,"given":"Po-Ren","family":"Hsueh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0368s4g32","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Laboratory Medicine, China Medical University Hospital, China Medical University","place":["Taichung, Taiwan"]},{"id":[{"id":"https:\/\/ror.org\/0368s4g32","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, China Medical University","place":["Taichung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","volume-title":"Bacterial priority pathogens list","author":"WHO","year":"2024","unstructured":"WHO. 2024. Bacterial priority pathogens list. World Health Organization:12-13, Geneva."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106878"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01332-21"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-024-00691-6"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz826"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.45.26723"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-025-02527-7"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10060652"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01580-4"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11060723"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02171-20"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.advms.2024.05.001"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-024-00762-y"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab352"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30554-1"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30731-3"},{"key":"e_1_3_4_18_2","unstructured":"CLSI. 2025. Performance standards for antimicrobial susceptibility testing; 35th informational supplement. CLSI Document M100-S35. Clinical and Laboratory Standards Institute Wayne PA"},{"key":"e_1_3_4_19_2","unstructured":"EUCAST. 2025. Breakpoint tables for interpretation of MICs and zone diameters version 15.0 January"},{"key":"e_1_3_4_20_2","unstructured":"FDA. 2025. Cefiderocol Injection. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/cefiderocol-injection"},{"key":"e_1_3_4_21_2","unstructured":"CLSI. 2024. Performance standards for antimicrobial disk susceptibility tests.CLSI document M02-Ed14. Clinical and Laboratory Standards Institute Wayne PA"},{"key":"e_1_3_4_22_2","unstructured":"EUCAST. 2025. EUCAST disk diffusion method manual version 13.0 January"},{"key":"e_1_3_4_23_2","unstructured":"EUCAST. 2024. Guidance document on broth microdilution testing of cefiderocol"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab018"},{"key":"e_1_3_4_25_2","unstructured":"EUCAST. 2025. Reading guide for disk diffusion method version 11.0 January"},{"key":"e_1_3_4_26_2","unstructured":"EUCAST. 2025. Routine and extended internal quality control for MIC determination and disk diffusionas recommended by EUCAST version 15.0 January"},{"key":"e_1_3_4_27_2","unstructured":"CLSI. 2024. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI Document M07-Ed12. Clinical and Laboratory Standards Institute Wayne PA"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01648-24"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106882"},{"key":"e_1_3_4_30_2","unstructured":"EUCAST. 2022. Cefiderocol: Rationale for EUCAST Clinical Breakpoints version 1.1"},{"key":"e_1_3_4_31_2","unstructured":"CLSI. 2023. Development of in vitro susceptibility test methods breakpoints and quality control parameters. CLSI Document M23-Ed6. Clinical and Laboratory Standards Institute Wayne PA"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.11.5102-5108.2004"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.1287"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.741940"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-021-04341-z"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-889"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae183"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.04.016"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00198-20"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01221-20"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1636"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01255-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01255-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:01:05Z","timestamp":1768399265000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.01255-25"}},"subtitle":[],"editor":[{"given":"Daniel J.","family":"Diekema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,14]]}},"alternative-id":["10.1128\/jcm.01255-25"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01255-25","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"2025-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01255-25"}}